ReviewFrontiers in immunology2026
Immune dysregulation in endometriosis: the T cell perspective.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- No difference in anxiety symptoms between women with unilateral and bilateral ovarian endometriosis: a prospective cross-sectional study.Annals of medicine · 2026Article
- Do Oxidative Stress-Modified Exosomes Contribute to Infertility in Endometriosis?International journal of molecular sciences · 2026Review
- Somatic Cancer Driver Mutation Analysis in Endometriosis with Tumor-like Presentations: A Case Series Study.Biomedicines · 2026Article
- Is Recurrent Endometriosis a Reprogrammed Disease? Molecular Persistence Beyond Surgical Clearance.Cells · 2026Review
- Contributions of T-helper 9 cells in endometriosis-associated inflammation and lesion growth.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Deciphering immune-inflammatory dysregulation in the endometriotic microenvironment: insights from single-cell omics and artificial intelligence.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a chronic inflammatory, hormone dependent disorder that affects more than 200 million women worldwide. Immune dysfunction has emerged as one of the predominant mechanisms facilitating endometriosis lesion growth and survival. In particular, T cell subsets are predominant effector immune cells within the complex endometriosis lesion microenvironment. T cell biology encompasses a highly regulated and diverse network of cellular differentiation, antigen recognition, and immune regulation, all of which play critical roles in immune homeostasis. This complexity becomes particularly relevant in endometriosis, as autologous lesions evade immune clearance within this sterile, non-pathogen-driven inflammatory milieu, highlighting a failure of immune surveillance and debris clearance. Indeed, aberrant T cell phenotypes, including skewed Th2 and regulatory subsets, promote an anti-inflammatory and tissue-remodeling environment in endometriosis. Despite advances in characterizing immune cell subsets, the mechanisms underlying T cell dysfunction and lesion persistence remain poorly defined. Here, we provide comprehensive insights into the diverse T cell subsets infiltrating endometriosis lesions and associated mechanisms that potentially contribute to endometriosis lesion establishment and subsequent survival. A systems-level understanding of T cell roles within the endocrine-immune microenvironment is essential for developing targeted immunotherapies and personalized interventions for this globally prevalent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.